Press Release Archives - Xtant Medical

Xtant Medical Reports Third Quarter 2024 Financial Results

November 12, 2024

Third Quarter Revenue Growth of 12% Reaffirms Full Year 2024 Revenue Guidance of $116 Million to $120 Million Representing Growth of 27% to 31% BELGRADE, MT / ACCESSWIRE / November 12, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on

Xtant Medical to Attend the 15th Annual Craig-Hallum Alpha Select Conference

November 11, 2024

BELGRADE, MT / ACCESSWIRE / November 11, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced announced that Sean Browne , CEO and Scott Neils , CFO will be attending the

Xtant Medical to Issue Third Quarter 2024 Financial Results on November 12, 2024

November 7, 2024

BELGRADE, MT / ACCESSWIRE / November 7, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the third quarter ended September

Xtant Medical Expands Product Portfolio with the Launch of the Cortera(R) Posterior Fixation System

September 23, 2024

BELGRADE, MT / ACCESSWIRE / September 23, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leading global medical technology company focused on the treatment of spinal disorders, is excited to announce the launch of the Cortera Posterior Fixation System, a comprehensive solution designed to streamline thoracolumbar fixation surgeries.

Xtant Medical Expands Product Portfolio with Launch of its own Viable Bone Matrix, OsteoVive(R) Plus

September 20, 2024

BELGRADE, MT / ACCESSWIRE / September 18, 2024 /) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced it has launched a new addition to its robust product portfolio, OsteoVive

Xtant Medical Reports Second Quarter 2024 Revenue Growth of 48%

August 8, 2024

Xtant Medical Reports First Quarter 2024 Revenue Growth of 55% and Raises Full Year 2024 Revenue Guidance

May 15, 2024

Expects Revenue for Full Year 2024 of $116 Million to $120 Million BELGRADE, MT, May 15, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and

Xtant Medical to Issue First Quarter 2024 Financial Results on May 15, 2024

May 13, 2024

BELGRADE, Mont. , May 13, 2024 -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the first quarter ended March 31, 2024, after

Xtant Medical Announces Launch of SimpliGraft™ and SimpliMax™ for Chronic and Acute Wounds

April 30, 2024

BELGRADE, Mont. , April 30, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the full commercial launch of two amniotic membrane allografts,

Xtant Medical Announces Record Full Year 2023 Revenue of $91.3 Million

April 1, 2024

Establishes Full Year 2024 Revenue Guidance of $112 Million - $116 Million BELGRADE, Mont. , April 01, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported

Xtant Medical to Issue Fourth Quarter and Full Year 2023 Financial Results on April 1, 2024

March 21, 2024

BELGRADE, Mont. , March 21, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the fourth quarter and

Xtant Medical Increases Revolving Credit Facility to $17 Million with MidCap Financial

March 7, 2024

BELGRADE, Mont. , March 07, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that the Company’s revolving credit agreement with MidCap Financial Trust